This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Anderson L.L., Thompson C.H., Hawkins N.A., Nath R.D., Petersohn A.A., Rajamani S. et al.:Antiepileptic activity of preferential inhibitors of persistent sodium current. Epilepsia, 2014, 55: 1274–1283.AndersonL.L.ThompsonC.H.HawkinsN.A.NathR.D.PetersohnA.A.RajamaniS.: Antiepileptic activity of preferential inhibitors of persistent sodium current. Epilepsia, 2014, 55: 1274–1283.Search in Google Scholar
Bell G.S., Mula M., Sander J.W.:Suicidality in people taking antiepileptic drugs: what is the evidence? CNS Drugs, 2009, 23: 281–292. doi:10.2165/00023210-200923040-00002.BellG.S.MulaM.SanderJ.W.: Suicidality in people taking antiepileptic drugs: what is the evidence?CNS Drugs, 2009, 23: 281–292. doi:10.2165/00023210-200923040-00002.Open DOISearch in Google Scholar
Bialer M., Johannessen S.I., Levy R.H., Perucca E., Tomson T., White H.S.:Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res., 2013,103: 2–30. doi: 10.1016/j.eplepsyres.2012.10.001.BialerM.JohannessenS.I.LevyR.H.PeruccaE.TomsonT.WhiteH.S.: Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res., 2013,103:2–30. doi: 10.1016/j.eplepsyres.2012.10.001.Open DOISearch in Google Scholar
Bocquet H., Bagot M., Roujeau J.C.:Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin. Cutan. Med. Surg., 1996, 15, 250–257.BocquetH.BagotM.RoujeauJ.C.: Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin. Cutan. Med. Surg., 1996, 15, 250–257.Search in Google Scholar
Calle A.M., Aguirre N., Ardila J.C., Cardona Villa R.:DRESS syndrome: A literature review and treatment algorithm. World Allergy Organ J., 2023, 16: 100673. doi: 10.1016/j.wao-jou.2022.100673.CalleA.M.AguirreN.ArdilaJ.C.Cardona VillaR.: DRESS syndrome: A literature review and treatment algorithm. World Allergy Organ J., 2023, 16: 100673. doi: 10.1016/j.wao-jou.2022.100673.Open DOISearch in Google Scholar
Christensen J., Vestergaard M., Mortensen P.B., Sidenius P., Agerbo E.:Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol., 2007, 6: 693–698.ChristensenJ.VestergaardM.MortensenP.B.SideniusP.AgerboE.: Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol., 2007, 6: 693–698.Search in Google Scholar
Cherubini E.:Phasic GABAA-mediated inhibition. In: Noebels J.L., Avoli M., Rogawski M.A. et al. (eds).: Jasper’s Basic Mechanisms of the Epilepsies [Internet]. 4th ed. Bethesda (MD): National Center for Biotechnology Information (US), 2012.CherubiniE.: Phasic GABAA-mediated inhibition. In: NoebelsJ.L.AvoliM.RogawskiM.A. (eds).: Jasper’s Basic Mechanisms of the Epilepsies [Internet]. 4th ed. Bethesda (MD): National Center for Biotechnology Information (US), 2012.Search in Google Scholar
Chung S.S., French J.A., Kowalski J., Krauss G.L., Lee S.K., Maciejowski M. et al.:Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology, 2020, 94: e2311–2322.ChungS.S.FrenchJ.A.KowalskiJ.KraussG.L.LeeS.K.MaciejowskiM.: Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology, 2020, 94: e2311–2322.Search in Google Scholar
Coleman C.I., Limone B., Sobieraj D.M., Lee S., Roberts M.S., Kaur R. et al.:Dosing frequency and medication adherence in chronic disease. J. Manag. Care Pharm., 2012, 18: 527–539.ColemanC.I.LimoneB.SobierajD.M.LeeS.RobertsM.S.KaurR.: Dosing frequency and medication adherence in chronic disease. J. Manag. Care Pharm., 2012, 18: 527–539.Search in Google Scholar
Connor G.:Long-term Cenobamate for Uncontrolled Focal Seizures in Patients Living in a Group Home or With Developmental Disability (P4-1.006). Neurology, 2023, 100 (Suppl. 2): 0191; doi: 10.1212/WNL.0000000000201804ConnorG.: Long-term Cenobamate for Uncontrolled Focal Seizures in Patients Living in a Group Home or With Developmental Disability (P4-1.006). Neurology, 2023, 100 (Suppl. 2): 0191; doi: 10.1212/WNL.0000000000201804Open DOISearch in Google Scholar
Elakkary S., Hagemann A., Klimpel D., Bien C.G., Brandt C.:A retrospective non-interventional study evaluating the pharma-cokinetic interactions between cenobamate and clobazam. Epilepsia, 2023, 64: e36– 42. https://doi.org/10.1111/epi.17515ElakkaryS.HagemannA.KlimpelD.BienC.G.BrandtC.: A retrospective non-interventional study evaluating the pharma-cokinetic interactions between cenobamate and clobazam. Epilepsia, 2023, 64: e36–42. https://doi.org/10.1111/epi.17515Search in Google Scholar
Elliott T., Ridley-Pryor T., Gienapp A.J., Wheless J.W.:Initial real-world experience with cenobamate in adolescents and adults: a single center experience. Pediatr. Neurol., 2022, 129: 19–23.ElliottT.Ridley-PryorT.GienappA.J.WhelessJ.W.: Initial real-world experience with cenobamate in adolescents and adults: a single center experience. Pediatr. Neurol., 2022, 129: 19–23.Search in Google Scholar
French J.A., Chung S.S., Krauss G.L., Lee S.K., Maciejowski M., Rosenfeld W.E. et al.:Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study. Epilepsia, 2021, 62: 2142–2150.FrenchJ.A.ChungS.S.KraussG.L.LeeS.K.MaciejowskiM.RosenfeldW.E.: Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study. Epilepsia, 2021, 62: 2142–2150.Search in Google Scholar
Gaitatzis A., Sisodiya S.M., Sander J.W.:The somatic comorbidity of epilepsy: a weighty but often unrecognized burden. Epilepsia, 2012, 53: 1282–1293.GaitatzisA.SisodiyaS.M.SanderJ.W.: The somatic comorbidity of epilepsy: a weighty but often unrecognized burden. Epilepsia, 2012, 53: 1282–1293.Search in Google Scholar
Greene S., Kwak C., Kamin M., Vernillet L.:The effect of cenobamate on the single dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects [abstract]. Clin. Pharmacol. Ther., 2019, 105 (suppl. 1): S97.GreeneS.KwakC.KaminM.VernilletL.: The effect of cenobamate on the single dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects [abstract]. Clin. Pharmacol. Ther., 2019, 105 (suppl. 1): S97.Search in Google Scholar
Guignet M., Campbell A., White H.S.:Cenobamate (XCOPRI): can preclinical and clinical evidence provide insight into its mechanism of action? Epilepsia, 2020, 61: 1–11.GuignetM.CampbellA.WhiteH.S.: Cenobamate (XCOPRI): can preclinical and clinical evidence provide insight into its mechanism of action?Epilepsia, 2020, 61: 1–11.Search in Google Scholar
Hirsch L.J., Weintraub D.B., Buchsbaum R., Spencer H.T., Straka T., Hager M. et al.:Predictors of lamotrigine-associated rash. Epilepsia, 2006, 47: 318–322. doi: 10.1111/j.1528-1167.2006.00423.xHirschL.J.WeintraubD.B.BuchsbaumR.SpencerH.T.StrakaT.HagerM.: Predictors of lamotrigine-associated rash. Epilepsia, 2006, 47: 318–322. doi: 10.1111/j.1528-1167.2006.00423.xOpen DOISearch in Google Scholar
Kanner A.M.:Suicidality in Patients With Epilepsy: Why Should Neurologists Care? Front. Integr. Neurosci., 2022, 16. https://doi.org/10.3389/fnint.2022.898547KannerA.M.: Suicidality in Patients With Epilepsy: Why Should Neurologists Care?Front. Integr. Neurosci., 2022, 16. https://doi.org/10.3389/fnint.2022.898547Search in Google Scholar
Motika P.V., Spencer D.C.:Treatment of epilepsy in the elderly. Curr. Neurol. Neurosci. Rep., 2016, 16: 96.MotikaP.V.SpencerD.C.: Treatment of epilepsy in the elderly. Curr. Neurol. Neurosci. Rep., 2016, 16: 96.Search in Google Scholar
Kim S.H., Lee H., Kim D.W.:Switching antiepileptic drugs to once-daily dosing regimens in epilepsy patients Acta Neurol Scand., 2021, 143: 51–55. doi: 10.1111/ane.13333Epub 2020 Aug 26.PMID: 32762074KimS.H.LeeH.KimD.W.: Switching antiepileptic drugs to once-daily dosing regimens in epilepsy patients Acta Neurol Scand., 2021, 143: 51–55. doi: 10.1111/ane.13333 Epub 2020 Aug 26.PMID: 32762074Open DOISearch in Google Scholar
Klein P., Aboumatar S., Brandt C., Dong F., Krauss G.L., Mizne S. et al.:Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology, 2022, 99: e989– 998.KleinP.AboumatarS.BrandtC.DongF.KraussG.L.MizneS.: Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology, 2022, 99: e989–998.Search in Google Scholar
Klein P., Devinsky O., French J., Harden C., Krauss G.L., Mc-Carter R. et al.:Suicidality risk of newer antiseizure medications: a meta-analysis. JAMA Neurol., 2021, 78: 1118–1127. doi:10.1001/jamaneurol.2021.2480.KleinP.DevinskyO.FrenchJ.HardenC.KraussG.L.Mc-CarterR.: Suicidality risk of newer antiseizure medications: a meta-analysis. JAMA Neurol., 2021, 78: 1118–1127. doi:10.1001/jamaneurol.2021.2480.Open DOISearch in Google Scholar
Krauss G.L., Klein P., Brandt C.:Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol., 2020, 19: 38–48. https://doi.org/10.1016/S1474-4422(19)30399-0KraussG.L.KleinP.BrandtC.: Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol., 2020, 19: 38–48. https://doi.org/10.1016/S1474-4422(19)30399-0Search in Google Scholar
Latimer D.R., Edinoff A.N., Ruff R.D., Rooney K.C., Penny K.M., Patel S.B. et al.:Cenobamate, a sodium channel inhibitor and positive allosteric modulator of GABAAion channels, for partial onset seizures in adults: A comprehensive review and clinical implications. Neurol. Int., 2021, 13: 252–265.LatimerD.R.EdinoffA.N.RuffR.D.RooneyK.C.PennyK.M.PatelS.B.: Cenobamate, a sodium channel inhibitor and positive allosteric modulator of GABAAion channels, for partial onset seizures in adults: A comprehensive review and clinical implications. Neurol. Int., 2021, 13: 252–265.Search in Google Scholar
Löscher W., Schmidt D.:Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia, 2006, 47: 1253–1284.LöscherW.SchmidtD.: Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia, 2006, 47: 1253–1284.Search in Google Scholar
Löscher W., Sills G.J., White H.S.:The ups and downs of alkyl-carbamates in epilepsy therapy: How does cenobamate differ? Epilepsia, 2021, 62: 596–614.LöscherW.SillsG.J.WhiteH.S.: The ups and downs of alkyl-carbamates in epilepsy therapy: How does cenobamate differ?Epilepsia, 2021, 62: 596–614.Search in Google Scholar
Lattanzi S., Trinka E., Zaccara G., Striano P., Del Giovane C., Silvestrini M. et al.:Adjunctive cenobamate for focal-onset seizures in adults: a systematic review and meta-analysis. CNS Drugs, 2020, 34: 1105–1120.LattanziS.TrinkaE.ZaccaraG.StrianoP.Del GiovaneC.SilvestriniM.: Adjunctive cenobamate for focal-onset seizures in adults: a systematic review and meta-analysis. CNS Drugs, 2020, 34: 1105–1120.Search in Google Scholar
Mula M.:Epilepsy and mood disorders. In: The comorbidities of epilepsy. M. Mula (ed.), Elsevier, 2019, pp 299–314.MulaM.: Epilepsy and mood disorders. In: The comorbidities of epilepsy. MulaM. (ed.), Elsevier, 2019, pp 299–314.Search in Google Scholar
Mula M., Kanner A.M., Schmitz B., Schachter S.:Antiepileptic drugs and suicidality: an expert consensus statement from the task force Commentary 29 on therapeutic strategies of the ILAE commission on neuropsychobiology. Epilepsia, 2013, 54: 199–203. doi:10.1111/j. 1528-1167.2012.03688.xMulaM.KannerA.M.SchmitzB.SchachterS.: Antiepileptic drugs and suicidality: an expert consensus statement from the task force Commentary 29 on therapeutic strategies of the ILAE commission on neuropsychobiology. Epilepsia, 2013, 54: 199–203. doi:10.1111/j. 1528-1167.2012.03688.xOpen DOISearch in Google Scholar
Nakamura M., Cho J.H., Shin H., Jang I.S.:Effects of ceno-bamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur. J. Pharmacol., 2019, 855: 175–82.NakamuraM.ChoJ.H.ShinH.JangI.S.: Effects of ceno-bamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur. J. Pharmacol., 2019, 855: 175–82.Search in Google Scholar
O’Dwyer R., Stern S., Wade, C., Guggilam A., Rosenfeld W.E.:Safety and Efficacy of Cenobamate for the Treatment of Focal Seizures in Older Patients (P4-1.002) Neurology, 2023, 100 (Suppl. 2): 1897. doi: 10.1212/WNL.0000000000202181O’DwyerR.SternS.WadeC.GuggilamA.RosenfeldW.E.: Safety and Efficacy of Cenobamate for the Treatment of Focal Seizures in Older Patients (P4-1.002)Neurology, 2023, 100 (Suppl. 2): 1897. doi: 10.1212/WNL.0000000000202181Open DOISearch in Google Scholar
Ontozry. Summary of product characteristics. Accessed July 2023: https://www.ema.europa.eu/en/documents/product-in-formation/ontozry-epar-product-information_en.pOntozry. Summary of product characteristics. Accessed July 2023: https://www.ema.europa.eu/en/documents/product-in-formation/ontozry-epar-product-information_en.pSearch in Google Scholar
O’Rourke G., O’Brien J.J.:Identifying the barriers to antiepileptic drug adherence among adults with epilepsy. Seizure, 2017, 45: 160–168.O’RourkeG.O’BrienJ.J.: Identifying the barriers to antiepileptic drug adherence among adults with epilepsy. Seizure, 2017, 45: 160–168.Search in Google Scholar
Peña-Ceballos J., Moloney P.B., Munteanu T., Doyle M., Colleran N., Liggan B. et al.:Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: A „real-world” retrospective study. Epilepsia, 2023, 64: 1225–1235. doi: 10.1111/epi.17549. Epub 2023 Feb 27. PMID: 36790345.Peña-CeballosJ.MoloneyP.B.MunteanuT.DoyleM.ColleranN.LigganB.: Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: A,,real-world” retrospective study. Epilepsia, 2023, 64: 1225–1235. doi: 10.1111/epi.17549. Epub 2023 Feb 27. PMID: 36790345.Open DOISearch in Google Scholar
Roberti R., De Caro C., Iannone L.F., Zaccara G., Lattanzi S., Russo E.:Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug-drug interactions and tolerability. CNS Drugs, 2021, 35: 609–618. doi: 10.1007/s40263-021-00819-88.RobertiR.De CaroC.IannoneL.F.ZaccaraG.LattanziS.RussoE.: Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug-drug interactions and tolerability. CNS Drugs, 2021, 35: 609–618. doi: 10.1007/s40263-021-00819-88.Open DOISearch in Google Scholar
Rosenfeld W.E., Abou-Khalil B., Aboumatar S., Bhatia P., Biton V., Krauss G.L. et al.:Post hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: effects of dose adjustments of concomitant antiseizure medications. Epilepsia, 2021, 62: 3016–3028.RosenfeldW.E.Abou-KhalilB.AboumatarS.BhatiaP.BitonV.KraussG.L.: Post hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: effects of dose adjustments of concomitant antiseizure medications. Epilepsia, 2021, 62: 3016–3028.Search in Google Scholar
Sander J.W., Rosenfeld W.E., Halford J.J., Steinhoff B.J,. Biton V., Toledo M.:Long-term individual retention with cenobamate in adults with focal seizures: pooled data from the clinical development program. Epilepsia, 2022, 63: 139–149.SanderJ.W.RosenfeldW.E.HalfordJ.J.SteinhoffB.J,. BitonV.ToledoM.: Long-term individual retention with cenobamate in adults with focal seizures: pooled data from the clinical development program. Epilepsia, 2022, 63: 139–149.Search in Google Scholar
Sharma R., Nakamura M., Neupane C., Jeon B.H., Shin H., Melnick S.M. et al.:Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate. Eur. J. Pharmacol., 2020, 879: 173117.SharmaR.NakamuraM.NeupaneC.JeonB.H.ShinH.MelnickS.M.: Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate. Eur. J. Pharmacol., 2020, 879: 173117.Search in Google Scholar
Singh A.:Cenobamate for treatment-resistant focal seizures: current evidence and place in therapy. J. Cent. Nerv. Syst. Dis., 2022, 14: 1–5.SinghA.: Cenobamate for treatment-resistant focal seizures: current evidence and place in therapy. J. Cent. Nerv. Syst. Dis., 2022, 14: 1–5.Search in Google Scholar
Smith M.C., Klein P., Krauss G.L., Rashid S., Seiden L.G., Stern J.M. et al.:Dose adjustment of concomitant antiseizure medications during cenobamate treatment: expert opinion consensus recommendations. Neurol. Ther., 2022, 11: 1705–1720.SmithM.C.KleinP.KraussG.L.RashidS.SeidenL.G.SternJ.M.: Dose adjustment of concomitant antiseizure medications during cenobamate treatment: expert opinion consensus recommendations. Neurol. Ther., 2022, 11: 1705–1720.Search in Google Scholar
Sperling M.R., Abou-Khalil B., Aboumatar S., Bhatia P., Biton V., Klein P. et al.:Efficacy of cenobamate for uncontrolled focal seizures: post hoc analysis of a phase 3, multicenter, open-label study. Epilepsia, 2021, 62: 3005–3015.SperlingM.R.Abou-KhalilB.AboumatarS.BhatiaP.BitonV.KleinP.: Efficacy of cenobamate for uncontrolled focal seizures: post hoc analysis of a phase 3, multicenter, open-label study. Epilepsia, 2021, 62: 3005–3015.Search in Google Scholar
Sperling M.R., Klein P., Aboumatar S., Gelfand M., Halford J.J., Krauss G.L. et al.:Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia, 2020, 61:1099–1108SperlingM.R.KleinP.AboumatarS.GelfandM.HalfordJ.J.KraussG.L.: Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia, 2020, 61:1099–1108Search in Google Scholar
Stafstrom C.E.: Persistent sodium current and its role in epilepsy. Epilepsy Curr., 2007, 7: 15. https://doi.org/10.1111/j.1535-7511.2007.00156.x.StafstromC.E.: Persistent sodium current and its role in epilepsy. Epilepsy Curr., 2007, 7: 15. https://doi.org/10.1111/j.1535-7511.2007.00156.x.Search in Google Scholar
Steinhoff B.J., Sanchez-Alvarez J., Majkowska-Zwolinska B., Maciejowski M., Steinhoff B.J, Rosenfeld W., Serratosa J.M, Brandt C., Klein P., Toledo M., Krauss G.L. et al.:Practical guidance for the management of adults receiving adjunctive cenobamate for the treatment of focal epilepsy – expert opinion. Epilepsy Behav., 2021, 123: 10827SteinhoffB.J.Sanchez-AlvarezJ.Majkowska-ZwolinskaB.MaciejowskiM.SteinhoffB.J, RosenfeldW.SerratosaJ.M, BrandtC.KleinP.ToledoM.KraussG.L.: Practical guidance for the management of adults receiving adjunctive cenobamate for the treatment of focal epilepsy – expert opinion. Epilepsy Behav., 2021, 123:10827Search in Google Scholar
St Louis E.K.:Truly “rational” polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects. Curr. Neuropharmacol., 2009, 7: 96–105.St LouisE.K.: Truly “rational” polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects. Curr. Neuropharmacol., 2009, 7: 96–105.Search in Google Scholar
Vernillet, L.; Greene, S.A.; Kamin, M.:Pharmacokinetics of Cenobamate: Results From Single and Multiple Oral Ascending-Dose Studies in Healthy Subjects. Clin. Pharmacol. Drug Dev., 2020, 9: 428–443.VernilletL.GreeneS.A.KaminM.: Pharmacokinetics of Cenobamate: Results From Single and Multiple Oral Ascending-Dose Studies in Healthy Subjects. Clin. Pharmacol. Drug Dev., 2020, 9: 428–443.Search in Google Scholar
Vernillet L., Kamin M.:Drug–drug interactions between cenobamate and other antiepileptic drugs: results from phase I studies with carbamazepine, phenobarbital, phenytoin, and divalproex sodium [abstract]. Clin. Pharmacol. Ther., 2018, 103 (Suppl. S1): 91.VernilletL.KaminM.: Drug–drug interactions between cenobamate and other antiepileptic drugs: results from phase I studies with carbamazepine, phenobarbital, phenytoin, and divalproex sodium [abstract]. Clin. Pharmacol. Ther., 2018, 103 (Suppl. S1): 91.Search in Google Scholar
Vernillet L., Greene S.A., Kamin M.:Pharmacokinetics of cenobamate: Results from single and multiple oral ascending-dose studies in healthy subjects. Clin. Pharmacol. Drug Dev., 2020, 4: 428–443.VernilletL.GreeneS.A.KaminM.: Pharmacokinetics of cenobamate: Results from single and multiple oral ascending-dose studies in healthy subjects. Clin. Pharmacol. Drug Dev., 2020, 4: 428–443.Search in Google Scholar
Villanueva V., Brandt C.:Efficacy and safety of cenobamate as adjunctive therapy in patients with uncontrolled focal seizures: results from two doubleblind, placebo-controlled, international studies [abstract]. Eur. J. Neurol., 2020, 27 (suppl. 1): 60.VillanuevaV.BrandtC.: Efficacy and safety of cenobamate as adjunctive therapy in patients with uncontrolled focal seizures: results from two doubleblind, placebo-controlled, international studies [abstract]. Eur. J. Neurol., 2020, 27 (suppl. 1): 60.Search in Google Scholar
Villanueva V., Santos-Carrasco D., Cabezudo-García P., Gómez-Ibáñez A., Garcés M., Serrano-Castro P. et al.:Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: Outcomes from an Expanded Access Program. Epilepsia Open, 2023 May 7. doi:10.1002/epi4.12757.VillanuevaV.Santos-CarrascoD.Cabezudo-GarcíaP.Gómez-IbáñezA.GarcésM.Serrano-CastroP.: Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: Outcomes from an Expanded Access Program. Epilepsia Open, 2023May7. doi:10.1002/epi4.12757.Open DOISearch in Google Scholar
Wang L., Mei X.-L.:Drug reaction with eosinophilia and systemic symptoms: retrospective analysis of 104 cases over one decade. Chin. Med. J., 2017, 130: 943–949.WangL.MeiX.-L.: Drug reaction with eosinophilia and systemic symptoms: retrospective analysis of 104 cases over one decade. Chin. Med. J., 2017, 130: 943–949.Search in Google Scholar
Vossler D.G.:Remarkably high efficacy of cenobamate in adults with focal-onset seizures: A double-blind, randomized, placebo-controlled trial. Epilepsy Curr., 2020, 20: 85–87.VosslerD.G.: Remarkably high efficacy of cenobamate in adults with focal-onset seizures: A double-blind, randomized, placebo-controlled trial. Epilepsy Curr., 2020, 20: 85–87.Search in Google Scholar
Wolfson A.R., Zhou L., Li Y., Phadke N.A., Chow O.A., Blumenthal K.G.:Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome identified in the electronic health record allergy module. J. Allergy Clin. Immuno Pract., 2019, 7: 633–640.WolfsonA.R.ZhouL.LiY.PhadkeN.A.ChowO.A.BlumenthalK.G.: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome identified in the electronic health record allergy module. J. Allergy Clin. Immuno Pract., 2019, 7: 633–640.Search in Google Scholar
Zaccara G., Lattanzi S.:Comorbidity between epilepsy and cardiac arrhythmias: implication for treatment. Epilepsy Behav., 2019, 97: 304–312. doi:10.1016/j.yebeh.2019.05.038.ZaccaraG.LattanziS.: Comorbidity between epilepsy and cardiac arrhythmias: implication for treatment. Epilepsy Behav., 2019, 97: 304–312. doi:10.1016/j.yebeh.2019.05.038.Open DOISearch in Google Scholar
Zaccara G., Franciotta D., Perucca E.:Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia, 2007, 48: 1223–1244. doi:10.1111/j.1528-1167.2007.01041.x.ZaccaraG.FranciottaD.PeruccaE.: Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia, 2007, 48: 1223–1244. doi:10.1111/j.1528-1167.2007.01041.x.Open DOISearch in Google Scholar
Zhang L., Wang J., Wang C.:Efficacy and safety of cenobamate in patients with uncontrolled focal seizures: a meta-analysis. Acta Neurol. Scand., 2021, 144: 58–66.ZhangL.WangJ.WangC.: Efficacy and safety of cenobamate in patients with uncontrolled focal seizures: a meta-analysis. Acta Neurol. Scand., 2021, 144: 58–66.Search in Google Scholar
Zhang N., Shon J., Kim M.J., Yu C., Zhang L., Huang S.M.:Role of CYP3A in Oral Contraceptives Clearance. Clin. Transl. Sci., 2018, 11: 251–260.ZhangN.ShonJ.KimM.J.YuC.ZhangL.HuangS.M.: Role of CYP3A in Oral Contraceptives Clearance. Clin. Transl. Sci., 2018, 11: 251–260.Search in Google Scholar
